Introduction
Cystic fibrosis (CF) is a fatal autosomal recessive disease affecting multiple organs. 1 The majority of mortality and morbidity is related to lung disease. 2 The CF gene defect impairs cystic fibrosis transmembrane regulator protein function leading to airway-surface-liquid depletion, loss of mucociliary clearance, and a vicious circle of inflammation and chronic bacterial infections. 3 An aggressive approach to treat CF lung disease has improved pulmonary outcomes and extended median predicted age of survival in the last 3 de-cades from 18 y of age in 1980 to 38.3 in 2010. 2 Inhaled medications constitute the main treatment options recommended for chronic maintenance of lung health in patients with CF. Recent guidelines have provided recommendations for the use of the following inhaled medications: tobramycin, dornase alfa, hypertonic saline, and ␤ 2 -adrenergic receptor agonists. 4, 5 The United States Cystic Fibrosis Foundation recommends the use of inhaled tobramycin in patients older than 6 y with mild, moderate, and severe lung disease who are chronically colonized by Pseudomonas aeruginosa. Tobramycin is administered at a dose of 300 mg twice daily on alternating months (28 d on/28 d off), and it has been shown to increase lung function and decrease pulmonary exacerbations. 4, 5 Tobramycin solution for inhalation is registered under the brand name Tobi (Novartis Pharmaceuticals Corporation, East Hanover, New Jersey) (300 mg/5 mL) and is used in combination with a Pari LC Plus reusable jet nebulizer (Pari Respiratory Equipment, Midlothian, Virginia) and a suitable compressor, which has a flow of 4 -6 L/min. 6 It is also available outside the United States as Bramitob (300 mg/4 mL) and used in combination with either Pari LC Plus reusable jet nebulizer and the Pari Turbo Boy compressor or Pari LC Sprint and Pari Boy Sx compressor. 7 Twice daily inhalation of tobramycin can take 40 min/d.
The Cystic Fibrosis Foundation also recommends the use of recombinant human dornase alfa for patients older than 6 y with a variable spectrum of CF lung disease. Dornase alfa (Pulmozyme) reduces viscoelasticity of CF sputum by hydrolyzing extracellular DNA released by neutrophils in the inflamed airways and therefore enhancing mucociliary clearance. 8 It is available in ampoules of 2.5 mg/2.5 mL, given once daily and used in jet nebulizers connected to a compressor. In clinical trials, device combinations such as Durable SideStream with Mobilaire, Durable SideStream with Porta-Neb, Hudson T Up-draft II with Pulmo-Aide, Respirgard II Nebulizer with PulmoAide, Pari LC Plus with Pari Proneb, and Pari Baby with Pari Proneb have been used. The estimated nebulization time ranges between 6 and 8 min. 9, 10 The Cystic Fibrosis Foundation also recommends the chronic use of nebulized hypertonic saline in patients with CF, 6 y of age and older, to improve lung function. 4, 5 By acting as an osmolar agent, hypertonic saline helps by hydrating the periciliary layer of the respiratory epithelium, hence enhancing airway clearance. 11 Administration of 4 mL of 7% saline twice daily improved FEV 1 , respiratory symptoms, and mucus clearance; inhalation time can take 15 min/d. For patients with CF, 6 y of age and older, the Cystic Fibrosis Foundation also recommends the chronic use of inhaled ␤ 2 -adrenergic receptor agonists to improve lung function. 4, 5 Nebulization time can reach 30 min.
Patients with CF use their nebulizers an average of 100 -120 min/d. Such use may reduce the performance of the compressors used to run these nebulizers. Manufacturers typically provide a 5-y warranty on the compressors, but they do not specify in their operations manuals the number of hours that they will run. Many third-party payers only allow compressor renewal every 5 y. Our clinical experience at the Arkansas Children's Hospital Cystic Fibrosis Care Center as well as frequent reports in CF-related professional Listservs indicate that the life span of compressors used by patients with CF is shorter than claimed by manufactures and covered by third-party payers.
Although several types of nebulizers are available, jet nebulizers are the most popular due to their low cost and widespread availability. Compressed air is needed for jet nebulizers to aerosolize liquid solutions or suspension and convert them into mist. 12, 13 Compressors constitute the only available air flow source at home and can be also used in hospital settings. The compressor gas flow/pressure relationship and patient-related factors affect the neb- 
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Current knowledge
Inhaled medications are often delivered at home for maintenance of lung health in patients with chronic respiratory disease. In combination with a jet nebulizer, compressors are used an average of 2 h/d. Each compressor/nebulizer has unique flow/pressure characteristics that affect medication delivery.
What this paper contributes to our knowledge
The long-term use of compressor/nebulizer units under simulated clinical conditions affects device performance. Pari Vios experienced significant changes in flow/pressure characteristics, including 2 units that failed. Periodic assessment of maximum flow may identify compressors prone to failure.
ulizer performance in terms of droplet size distribution and drug output rate. 14, 15 Lower gas flows lead to longer nebulization time and larger particle size aerosols. 15 The former hinders adherence to therapies, and the latter could alter the site of intrapulmonary deposition. Therefore, information about performance of compressor/nebulizer systems is important for patient care.
Although several authors have reported the characteristics of different compressors and nebulizers, little is known about the effect of long-term use on their performance. [16] [17] [18] [19] [20] Standaert et al 21 determined particle size distribution and output rate of the Pari LC durable nebulizer after 100 runs and reported that particle size remained stable.
In this study, we evaluated the performance of 3 pairs of compressor/nebulizer combinations over a 24-wk period of use typical of a patient with CF. We hypothesized that such use of compressor/nebulizer units will affect their flow/pressure, drug output, and aerosol characteristics. These changes are expected due to progressive deterioration of the compressor/nebulizer units and could have relevant implications for lung deposition and medication efficacy of aerosol treatments. In addition, we hypothesized the presence of differences in performance among different compressor/nebulizer systems.
Methods
Compressors and Nebulizers
Four new compressor units from 3 different brands were used in our study with the reusable nebulizer recommended by the manufacturers: Pari Vios compressor with Pari LC Plus reusable nebulizer (Pari Respiratory Equipment), Pulmo-Aide model 5650D compressor with Viox 1 reusable nebulizer (DeVilbiss Healthcare, Somerset, Pennsylvania), and Inspiration Elite model HS456 compressor with SideStream Plus model HS870 durable nebulizer (Philips Respironics, Parsippany, New Jersey). The Viox nebulizer is a constant output nebulizer, whereas Pari LC Plus and SideStream Plus are breath-enhanced nebulizers. The Inspiration Elite compressor has a self-resetting pressure relief valve that opens at 33 psi. The technical specifications provided by the manufacturers can be seen in Table 1 . These devices were chosen because they are the most commonly used and their manufacturers advertise their use for treatment of cystic fibrosis.
Study Design
Each compressor/nebulizer was operated without a solution for 1 h twice daily, 5 d/wk for 24 wk. The corresponding nebulizer was connected to each compressor. The same combinations of compressor/nebulizer units were used through the study. Environmental temperature and humidity were recorded at time of operation (23°C Ϯ 1.4°C and 42.6% Ϯ 5.7%, respectively). Measurements of flows and pressures were done at wk 0, 6, 12, 18, and 24. Breathing simulation testing and particle size distribution measurements were done at wk 0, 12, and 24. Compressor filters were periodically reviewed for presence of dirt. The study was performed at the Pediatric Aerosol Research Laboratory, Arkansas Children's Hospital Research Institute, Little Rock, Arkansas.
Flow and Pressure Measurements
Previously published methodologies were used to measure flow and pressure characteristics of compressor/nebulizer systems (Fig. 1) . 16, 17, 19 The outlet of each compressor was connected in line with tubing to a pressure meter with a transducer with a maximum of 72. flows similar to MF/NEB to 2 L/min, and then flow was decreased from 2 L/min to 0 L/min. These resulted in 12, 17, and 17 data points for Vios, Pulmo-Aide, and Inspiration Elite, respectively. Flow was adjusted with the needle valve, and pressure was measured at each flow. The pressure that the compressor developed at zero flow (needle valve completely closed) was recorded as the maximal pressure (MP). Measurements were done after 2 min of operation. The nebulizer without a solution was then connected to the flow meter, and MF/NEB and the pressure measured at MF/NEB (P/NEB) were recorded.
Particle Size Analysis
Particle size distribution was measured by cascade impaction. A Next Generation Impactor (NGI, MSP Corporation, Shoreview, Minnesota) calibrated at 15 L/min was cooled to 4°C for 90 min and used within 5 min of removal from the refrigerator. 22 Albuterol sulfate (2.5 mg/3 mL, Nephron Pharmaceuticals, Orlando, Florida) was loaded in the nebulizer. The nebulizer was connected to the inlet of the induction port of the NGI and was operated for 4 min (Fig. 2) . Air entrainment was allowed through the T-piece in the Viox nebulizer and through the inspiratory valve in the Pari LC Plus and SideStream Plus nebulizers. Upon completion, all the collection cups, internal and external filters, and nebulizer cup were diluted with ultrapure water and tested for albuterol concentration via spectrophotometry at 276 nm (BioMate 3 UVvisible spectrophotometer, Thermo Electron Corporation, Waltham, Massachusetts). 22 The following parameters were calculated using CITDAS 3.1 software (Copley Scientific, Nottingham, United Kingdom) according to United States Pharmacopeia and European Pharmacopeia recommendations: mass median aerodynamic diameter (MMAD), geometric SD (GSD), and percentage of drug mass contained in particles Ͻ 5 m (P% Ͻ 5). 22 Nebulizers were disassembled, cleaned with ultrapure water, and air-dried.
Breathing Simulation
This methodology is used to study aerosol output of nebulizers and allows an accurate evaluation of devices that have an increase in their aerosol output during inspiration, such as breath-enhanced nebulizers. 23 A breathing simulator is a computerized piston pump that allows programming of respiratory parameters to mimic different breathing conditions. Calibration of breathing simulator (Pari Compass) was verified at the beginning of each testing by a mass flow meter (model 4043, TSI, Shoreview, Minnesota) and its associated software. 24 Nebulizer dry weight was obtained while still empty using a precision scale. Albuterol sulfate (2.5 mg/3 mL, Nephron Pharmaceuticals Corporation) was loaded in the nebulizer, and a new weight was obtained. The nebulizer was connected to the breathing simulator. A low dead space filter was interposed between them (inspiratory filter). A filter holder (Pari Respiratory Equipment) with a one-way valve was connected to the nebulizer to capture the exhaled aerosol (expiratory filter) to minimize operator exposure (Fig. 3) . 25 New filters (Pari Respiratory Equipment) were placed at the beginning of each experiment. The nebulizer was connected to the compressor and operated for 10 min and then reweighed to obtain the final weight. The following breathing pattern was used: tidal volume 500 mL, breathing rate 12 breaths/min, inspiratory time 1.7 s, and inspiratoryexpiratory ratio 1:2. After completion of nebulization, 5 mL of pure water were added to the nebulizer cup. The nebulizer was reweighed and then swirled, and the solution was tested for albuterol concentration. Albuterol remaining in the nebulizer cup was calculated as follows: ([final weight ϩ 5 mL of pure water] Ϫ dry weight) ϫ albuterol concentration. The inspiratory filter was placed in a 50-mL tube with 10 mL of ultrapure water, and after vigorous shaking the solution was tested for albuterol concentration with spectrophotometry. The expiratory filter was dis- Fig. 2 . Experimental setup used to measure particle size of aerosols generated by compressor/nebulizer systems.
carded. Nebulizers were disassembled, cleaned with ultrapure water, and air-dried. Inhaled mass (IM, g) was defined as the amount of the albuterol captured by the inspiratory filter. Inhaled mass in the respirable range (IM-RR) was calculated as (IM ϫ P% Ͻ 5)/100.
Statistical Analysis
There were 5 parameters of interest related to pressure and flow measurements: MF, MP, MF/NEB, P/NEB, and slope of flow/pressure relationship without nebulizer (MF/MP slope). A nonlinear model of the form pressure ϭ a ϫ exponential function (b ϫ flow) was fit to the data, which provided the slope and maximal pressure estimates using the 5% level of significance. The Dunnet test was used to compare maximal pressure, flow, and flow/ pressure relationship slope at each time level to time zero. Analysis of variance followed by Tukey test was used to compare performance among the brands at wk 0, 6, 12, 18, and 24. Analysis of variance was used to compare particle size characteristics and breathing simulation results across devices. Analysis of variance for repeated measures was used to compare particle size characteristics and breathing simulation results at wk 0, 12, and 24 for each specific device. The Bonferroni method was used for post hoc analysis when multiple comparisons were required. A P value Ͻ .05 was considered statistically significant. A statistical software package was used for data analysis (SAS 9.3, SAS Institute, Cary, North Carolina).
Results
The 4 tested units of Inspiration Elite and Pulmo-Aide compressors completed all planned studies. Two units of the Vios completed all planned studies. One unit stopped running after d 5 of wk 11 with a total run of 110 h. Another unit completed all pressure/flow and simulation breathing studies, but, although the compressor was running, no aerosol was produced and no drug was recovered in the NGI at wk 24. This was verified in triplicate. Therefore, the n for the Vios brand were 4 and 3 before and after wk 11, respectively, for all measurements except for NGI at wk 24, when n was 2.
Flow and Pressure
The flow/pressure relationship is depicted in Figure 4 .
MF and MF/NEB. Pari Vios experienced a decline in MF at each time level compared with wk 0 without statistical significance (see Table 2 in text and Table 1 in the supplementary material available at http://www.rcjournal. com). However, the unit that stopped running at the end of wk 11 showed a decrease in MF from 9 L/min at baseline to 7 L/min at wk 6. Additionally, the unit that malfunctioned in wk 24 showed a decrease in MF from 9 L/min at baseline to 5 L/min at wk 18. Vios also had a decline in MF/NEB with time, which became statistically significant at wk 24 (P ϭ .045). The unit that malfunctioned in wk 24 had a decrease in MF/NEB from 4.5 L/min to 4 L/min and 3.5 L/min at wk 12, 18, and 24, respectively.
Pulmo-Aide and Inspiration Elite maintained baseline MF and MF/NEB measurements throughout the 24-wk period. Pari Vios MF and MF/NEB were lower than PulmoAide and Inspiration Elite at all times (P Ͻ .05). There was no difference in MF values between Pulmo-Aide and Inspiration Elite, but MF/NEB was higher in Pulmo-Aide than Inspiration Elite at all times (P Ͻ .05). Vios and Pulmo-Aide demonstrated higher MP than Inspiration Elite. When performing all pairwise comparisons among the brands, Vios had greater MP than Inspiration Elite at all times except in wk 18. Pulmo-Aide was consistently greater than Inspiration Elite with significant differences at all times except at wk 6. Vios had greater MP than Pulmo-Aide at wk 0 (P Ͻ .001), 6, and 12. The trend is reversed at wk 18 (P Ͻ .001) and wk 24, where PulmoAide had greater MP compared with Vios. P/NEB was different among different brands with Inspiron Elite greater than Vios and greater than Pulmo-Aide (P Ͻ .05). P/NEB remained stable for Pulmo-Aide and Inspiration Elite, but declined for Vios. The latter had a significant decline starting in wk 18.
MF/MP Slope. The brands behaved in a similar pattern at all times (see supplementary Table 1 and Fig. 1 in the material available at http://www.rcjournal.com). Pari Vios tended to have a greater absolute value of the MF/MP slope compared with Pulmo-Aide and Inspiration Elite. Pulmo-Aide tended to have a greater absolute value than Inspiration Elite. The difference in the slope when performing all pairwise comparisons was statistically significant with few exceptions. For wk 12, 18, and 24, statistical significance was not achieved, but the trend of Pari Vios having a greater slope than the other brands remained. In addition, Pari Vios had a greater variation around its trend compared with Pulmo-Aide and Inspiration Elite. This was especially true for wk 6 -24, in which the standard error of the slope for Pari Vios was always greater than for the other 2 brands.
The Vios unit that stopped running at the end of wk 11 showed a significantly lower pressure at wk 6 while the flow was set at 2.5 L/min. The other unit that malfunctioned at wk 24 had lower pressures but these were not different from the other units.
Particle Size Analysis
All brands maintained baseline MMAD by wk 24 (see Table 3 in text and Table 2 in the supplementary material available at http://www.rcjournal.com). Pari Vios had larger MMAD than Pulmo-Aide and Inspiration Elite at all times, but it was only statistically significant at wk 0 for ViosPulmo-Aide (P ϭ .04) and at wk 24 for Vios-Inspiration Elite (P ϭ .004). Inspiration Elite had smaller MMAD than PulmoAide, with significance only at wk 12 (P Ͻ .001).
Vios and Pulmo-Aide had a decrease in GSD at wk 24 compared with baseline (P Ͻ .001). Inspiration Elite did not have significant change in GSD by wk 24. Vios had significantly higher GSD than Pulmo-Aide at all times and higher GSD than Inspiration Elite at wk 0 and 12. Inspiration Elite had a larger GSD than Pulmo-Aide at wk 24.
P% Ͻ 5 had no significant change with time for all brands. Inspiration Elite trended to have higher P% Ͻ 5, followed by Pulmo-Aide and then Vios. The difference was significant compared with Vios at wk 24 (P ϭ .006) and with Pulmo-Aide at wk 12 (P ϭ .009).
Breathing Simulation
Vios and Inspiration Elite maintained baseline IM by the end of the study compared with baseline (see Table 3 in text  and Table 2 in the supplementary material available at http:// www.rcjournal.com). Pulmo-Aide experienced significant increase in IM at wk 24 (P Ͻ .001). There were differences among the brands. Inspiration Elite had the highest IM, with significance achieved in comparison to Pulmo-Aide at wk 0 and 12. Vios had higher IM than Pulmo-Aide at wk 0 and 12, but at wk 24 Pulmo-Aide was higher than Vios.
Pulmo-Aide had a significant increase in IM-RR at wk 12 and 24, but the others did not experience change. Inspiration Elite had the highest IM-RR among the brands, with significance at wk 0 and 12 when compared with Pulmo-Aide (2.9-and 2.4-fold difference, respectively). Vios had higher IM-RR than Pulmo-Aide that was significant at wk 0 and 12 (1.6-fold difference).
Discussion
This study provides flow/pressure and drug output characteristics of 3 compressor/nebulizer combinations commonly used by patients with CF and evaluates their performance over a 24-wk period of use typical of that population. It also shows differences in the performance among brands, which could provide data to practitioners to help them in the device selection process. These data should also provide manufacturers with additional information to help them improve their products.
Baseline flow and pressure values matched manufacturers' specifications, except for Pari Vios, which had higher MF and MP than specified. Comparison of baseline data with previously published compressor/nebulizer characteristics was not possible because none had used combinations similar to those used in our study . 16-20 In agreement with Smith et al, 16 who studied other compressor/nebulizer combinations, we found that different compressor/nebulizer combinations have different flow/pressure relationships.
Pari Vios was the only compressor/nebulizer system that had significant declines in MF/NEB, MP, and P/NEB. Two units of Vios/Pari LC Plus stopped working by the end of the study. A decrease in MF and MF/NEB identified compressors that would soon fail. Practitioners need to be aware of this occurrence and have a contingency plan prepared so patients do not miss treatments for lack of a working compressor.
One could speculate that the 2 compressors that stopped working were faulty from the beginning. However, a careful review of the MP data shows that they all worked appropriately at wk 0, as noted by a SD representing 1.4% of the mean. On wk 6, the SD represented 24% of the mean, mainly due to the contribution of the unit that would stop working before wk 12. During wk 12 and 18, the SD represented 7-8% of the mean, showing that the second unit that malfunctioned in wk 24 was performing at the same level as the other ones. In addition, the progressive decline of the different units can be visualized (see Fig. 1 in the supplementary material available at http://www. rcjournal.com).
In contrast to Vios, flow and pressure characteristics remained stable for Pulmo-Aide and Inspiration Elite.
Maximal flows significantly varied across brands, but nebulizer design seemed to be more important than MF to determine IM-RR.
In agreement with Standaert et al, 21 we found that all compressor/nebulizer combinations maintained baseline MMAD. Their study was limited to 100 runs, and ours was 14 obtained using arformoterol inhalation solution. We speculate that the stable IM-RR showed by the Pari Vios brand could be partially explained by the pressure fluctuations (MP) noted during the study. Another possible explanation is that the compressors will maintain a stable IM-RR while they remain operational. A third explanation for this finding could be the large individual variance at each time point.
Clinicians need to be aware of the differences in IM-RR that exist among different compressor/nebulizer combinations. Although a nearly 3-fold difference may not be meaningful for albuterol, it could result in either underdosing or overdosing of other drugs, especially those with a narrow therapeutic index.
There are some limitations to the present study. Devices were operated for a total of 2 h daily without a solution, which could potentially minimize the effect of such use on the compressor/nebulizer systems and their characteristics. In addition, albuterol was the only medication used for particle size and breathing simulation measurements. If other solutions/suspensions had been used, characteristics could have potentially differed. Another limitation is that we tested only one breathing pattern (adult). However, although we expect the IM to be lower with a pediatric breathing pattern, we do not think that the choice of breathing pattern affects the validity of the findings. Longer studies with a larger number of units are needed to either verify or refute our findings. In addition, real life studies using the devices patients use daily are necessary to complement our findings.
Implication of the Findings
We found that not all compressor/nebulizer combinations can endure the use that occurs during CF care. In addition, significant differences among combinations in several outcome measures are present. Data would help healthcare providers to come up with recommendations of which compressor/nebulizer systems are better suited for actual use by patients with CF. Further longitudinal studies would have more relevant clinical implications than studying the characteristics of compressor/nebulizer units at the beginning of their use. Manufacturers need to consider IM ϭ inhaled mass IM-RR ϭ inhaled mass in the respirable range improving the ability of their compressors to withstand long-term use such as occurs in patients with CF. Because a decrease in MF is expected to increase treatment times, patients with CF should be asked at their clinic visits whether their treatments are taking longer. Periodic assessments of MF could also be easily implemented in clinical settings to screen for compressor units that are likely to fail.
Conclusions
The long-term use of compressor/nebulizer units under conditions similar to those of patients with CF affects their performance. Pari Vios was the most affected brand, experiencing significant changes in their flow/pressure characteristics, including 2 units that stopped working by the end of the study. Periodic assessment of MF could help identify compressors that will fail. IM and IM-RR remained stable throughout the study. Inspiration Elite was the brand most able to keep baseline flow/pressure characteristics and also had the smallest MMAD, highest P% Ͻ 5, and IM-RR through the study.
